-
1
-
-
84993811110
-
Immunogenicity and other problems associated with the use of biopharmaceuticals
-
Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2011; 2: 113-128.
-
(2011)
Ther Adv Drug Saf
, vol.2
, pp. 113-128
-
-
Tovey, M.G.1
Lallemand, C.2
-
2
-
-
0035760892
-
Thrombocytopenia caused by the development of antibodies to thrombopoietin
-
Li J, Yang C, Xia Y etal. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
-
(2001)
Blood
, vol.98
, pp. 3241-3248
-
-
Li, J.1
Yang, C.2
Xia, Y.3
-
3
-
-
84962971532
-
-
Accessed 8 July
-
Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf. Accessed 8 July 2015.
-
(2015)
-
-
-
4
-
-
79953032228
-
LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
-
Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434-438.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 434-438
-
-
Barrington, P.1
Chien, J.Y.2
Tibaldi, F.3
Showalter, H.D.4
Schneck, K.5
Ellis, B.6
-
5
-
-
77952756104
-
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
-
Glaesner W, Vick AM, Millican R etal. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010; 26: 287-296.
-
(2010)
Diabetes Metab Res Rev
, vol.26
, pp. 287-296
-
-
Glaesner, W.1
Vick, A.M.2
Millican, R.3
-
6
-
-
0035859982
-
From genome to vaccine: in silico predictions, ex vivo verification
-
De Groot AS, Bosma A, Chinai N etal. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001; 19: 4385-4395.
-
(2001)
Vaccine
, vol.19
, pp. 4385-4395
-
-
De Groot, A.S.1
Bosma, A.2
Chinai, N.3
-
7
-
-
84930074468
-
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
-
Blonde L, Jendle J, Gross J etal. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015; 385: 2057-2066.
-
(2015)
Lancet
, vol.385
, pp. 2057-2066
-
-
Blonde, L.1
Jendle, J.2
Gross, J.3
-
8
-
-
84914666192
-
Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus
-
Ferdinand KC, White WB, Calhoun DA etal. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014; 64: 731-737.
-
(2014)
Hypertension
, vol.64
, pp. 731-737
-
-
Ferdinand, K.C.1
White, W.B.2
Calhoun, D.A.3
-
9
-
-
84962338740
-
Efficacy and safety of once weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)
-
Giorgino F, Benroubi M, Sun J-H, Zimmermann AG, Pechtner V. Efficacy and safety of once weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015; 38: 2241-2249.
-
(2015)
Diabetes Care
, vol.38
, pp. 2241-2249
-
-
Giorgino, F.1
Benroubi, M.2
Sun, J.-H.3
Zimmermann, A.G.4
Pechtner, V.5
-
10
-
-
84904992244
-
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)
-
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149-2158.
-
(2014)
Diabetes Care
, vol.37
, pp. 2149-2158
-
-
Nauck, M.1
Weinstock, R.S.2
Umpierrez, G.E.3
Guerci, B.4
Skrivanek, Z.5
Milicevic, Z.6
-
11
-
-
84904360390
-
Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)
-
Umpierrez G, Povedano ST, Manghi FP, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37: 2168-2176.
-
(2014)
Diabetes Care
, vol.37
, pp. 2168-2176
-
-
Umpierrez, G.1
Povedano, S.T.2
Manghi, F.P.3
Shurzinske, L.4
Pechtner, V.5
-
12
-
-
79953035319
-
The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
-
Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ III. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011; 13: 418-425.
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 418-425
-
-
Umpierrez, G.E.1
Blevins, T.2
Rosenstock, J.3
Cheng, C.4
Anderson, J.H.5
Bastyr, E.J.6
-
13
-
-
84905012167
-
Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
-
Wysham C, Belvins T, Arakaki R etal. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-2167.
-
(2014)
Diabetes Care
, vol.37
, pp. 2159-2167
-
-
Wysham, C.1
Belvins, T.2
Arakaki, R.3
-
14
-
-
84908331441
-
Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
-
Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J 2014; 61: 949-959.
-
(2014)
Endocr J
, vol.61
, pp. 949-959
-
-
Terauchi, Y.1
Satoi, Y.2
Takeuchi, M.3
Imaoka, T.4
-
15
-
-
84866435806
-
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
-
Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012; 29: 1260-1267.
-
(2012)
Diabet Med
, vol.29
, pp. 1260-1267
-
-
Grunberger, G.1
Chang, A.2
Garcia Soria, G.3
Botros, F.T.4
Bsharat, R.5
Milicevic, Z.6
-
16
-
-
84860250733
-
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
-
Fineman MS, Mace KF, Diamant M etal. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546-554.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 546-554
-
-
Fineman, M.S.1
Mace, K.F.2
Diamant, M.3
-
17
-
-
84962925548
-
-
Version 15.0. Chantilly, Virginia. March 2012. Accessed 8 July 2015.
-
International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (IHC). Introductory Guide for Standardised MedDRA Queries (SMQs) Version 15.0. Chantilly, Virginia. March 2012. Available from URL: http://www.meddra.org/sites/default/files/guidance/file/smq_intguide_15_0_english.pdf. Accessed 8 July 2015.
-
Introductory Guide for Standardised MedDRA Queries (SMQs)
-
-
-
18
-
-
84903597970
-
Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations
-
Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014; 16: 658-673.
-
(2014)
AAPS J
, vol.16
, pp. 658-673
-
-
Shankar, G.1
Arkin, S.2
Cocea, L.3
-
19
-
-
84874434023
-
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial
-
Rosenstock J, Balas B, Charbonnel B etal. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care 2013; 36: 498-504.
-
(2013)
Diabetes Care
, vol.36
, pp. 498-504
-
-
Rosenstock, J.1
Balas, B.2
Charbonnel, B.3
|